SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as the software sector navigates a significant sell-off driven by "AI fear," sparking intense community debate on whether AI will disrupt or enhance the enterprise giant. Despite news of workforce adjustments and a new government contract, many investors are frustrated by ongoing price declines, viewing it as an oversold opportunity potentially exacerbated by market manipulation.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to mixed community reactions following its Q4 earnings report, which showed a beat on adjusted EPS but fueled ongoing concerns about revenue growth and increasing debt. The community is sharply divided between those who see a value opportunity amidst its current valuation and others drawing negative parallels to the broader fintech sector and companies like PayPal.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending due to its significant Q4 earnings and revenue miss, sharply contrasted by an ambitious 2026 outlook that projects profitability and substantial revenue growth, primarily driven by strong membership gains in the ACA marketplace. This has ignited a fierce debate within the community regarding the company's future trajectory and the credibility of its aggressive guidance.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is at a pivotal moment as its Q4 earnings report is highly anticipated, with the community actively debating whether the recent significant sell-off presents a buying opportunity. Despite broader software sector concerns and increased competition, many highlight Datadog's critical role in monitoring AI-driven cloud infrastructure and its strong customer relationships, while some analysts have adjusted price targets reflecting mixed expectations for performance amidst a valuation reset.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following strong Q4 earnings, optimistic FY2026 guidance, and reaffirmed targets for profitability by 2027, with the community actively discussing its potential as the 'Amazon of Africa' amidst bullish analyst coverage.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to a strong Q4 2025 earnings beat, surpassing user growth and profitability forecasts with notable MAU additions and improved margins. The community is bullish, highlighting the company's robust free cash flow and optimistic outlook for re-accelerated growth.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending as investors digest mixed Phase 2b results for its alopecia areata drug, with community discussion focused on the significance of efficacy data achieved after excluding some patients and the drug's strong safety profile, alongside ongoing speculation about a potential Lilly settlement.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending following its earnings report, which revealed a revenue miss primarily due to weak North American demand, sparking community discussions about its recent rally and overbought conditions despite an earnings per share beat and strong performance in the broader consumer staples sector.

S&P Global, Inc. engages in the provision of transparent and independent ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. It operates through the following segments: Market Intelligence, Ratings, Commodity Insights, Mobility, Indices, and Engineering Solutions. The Market Intelligence segment provides multi-asset-class data and analytics integrated with purpose-built workflow solutions. The Ratings segment is involved in credit ratings, research, and analytics, offering investors and other market participants information, ratings, and benchmarks. The Commodity Insights segment focuses on information and benchmark prices for the commodity and energy markets. The Mobility segment offers solutions serving the full automotive value chain including vehicle manufacturers, automotive suppliers, mobility service providers, retailers, consumers, and finance and insurance companies. The Engineering Solutions segment engages in advanced knowledge discovery technologies, research tools, and software-based engineering decision engines to advance innovation, maximize productivity, improve quality, and reduce risk. The company was founded by James H. McGraw and John A. Hill in 1917 and is headquartered in New York, NY.

S&P Global Inc

S&P Global is trending as its latest guidance signaled slower growth and missed analyst estimates, fueling community discussion amidst broader concerns that powerful new AI models, such as Anthropic's Claude Opus 4.6, could significantly disrupt the financial data and analytics sector, though many also view the sharp sell-off as an overreaction and a buying opportunity.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending due to recent Medicare coverage for its ultrasensitive molecular residual disease (MRD) test in breast cancer and accelerating test volumes, igniting community optimism for further reimbursement approvals in lung cancer and I/O monitoring. Investors are increasingly bullish on the company's long-term potential in the expanding liquid biopsy market, despite underlying concerns about management's communication.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy.</li><li>In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</li><li>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</li></ul><p>Kazia Therapeutics Inc.’s (KZIA) shares rose more than 6% in Friday’s pre-market trade after the company announced new preclinical and translational data for NDL2, a protein degrader.</p><p>The Sydney, Australia-based oncology-focused pharmaceutical company stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity. This includes the combination of NDL2 with anti-PD-1 therapy, which uses monoclonal bodies such as nivolumab or pembrolizumab to block the PD-1 protein on T-cells.</p><p>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KZIA">Kazia Therapeutics</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘high’ levels.</p><h2 class="st-heading-2">Highlights Of New NDL2 Data</h2><p>Kazia stated that in murine triple-negative breast cancer (TNBC) preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy. In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</p><p>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</p><p>The company added that no toxicity or hemolysis was observed, while noting that the immune checkpoint function at the cell surface was preserved, and the plasma stability was favorable.</p><h2 class="st-heading-2">What Is NDL2 Aimed At?</h2><p>Kazia is currently developing the NDL2 protein degrader to selectively eliminate nuclear PD-L1 (Programmed Death-Ligand 1).</p><p>PD-L1 is a protein found on the surface of many cancer cells as well as some normal cells. The protein helps these cells evade the immune system.</p><p><a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> is down 6% year-to-date and 12% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-after-sofi-technologies-reports-1b-quarterly-revenue-first-time/cmySKHPR4ST"><strong>SOFI Stock Rises Pre-Market After SoFi Technologies Reports $1B Quarterly Revenue For The First Time</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Representative image of a trending stock chart.

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

Equity

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear...

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Kazia Therapeutics Reports...

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics to Participate in J.P. Morgan Healthcare...

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Kazia Therapeutics Regains Full Nasdaq Listing Compliance Kazia Therapeutics Regains Full Nasdaq Listing Compliance PR Newswire SYDNEY, Dec. 22, 2025 Restoration of Nasdaq compliance follows $50...

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations...

What's Going On With Cancer Firm Kazia Therapeutics

Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical development and extend cash runway.read more...

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities PR Newswire...

<ul class="summary-bullets"><li>The patient remains on therapy and under active clinical monitoring, the company said.</li><li>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient.</li><li>Kazia also raised concerns on Tuesday regarding a potential suspension or delisting of its shares from the Nasdaq.</li></ul><p>Shares of cancer drug developer Kazia Therapeutics Limited (KZIA) were in the spotlight on Wednesday after the company said that a stage IV triple-negative breast cancer patient treated with a combination of its lead program Paxalisib with Pembrolizumab and standard chemotherapy has achieved an initial immune-complete response.</p><p>An immune-complete response means the complete disappearance of all signs of cancer following immunotherapy. It is also known as complete remission.</p><p>KZIA shares traded 42% higher on Wednesday morning at the time of writing.</p><h2 class="st-heading-2">Data And Takeaways</h2><p>As per Kazia, complete responses in stage IV metastatic TNBC are exceedingly uncommon and may suggest enhanced biological activity of the combination regimen, warranting continued follow-up.</p><p>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient. After about three months of therapy, a scan performed demonstrated complete metabolic resolution of all previously identified lesions, consistent with an initial immune-complete response, the company said.</p><p>The patient remains on therapy and under active clinical monitoring, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/kazia-therapeutics-achieves-initial-icr-immune-complete-response-in-metastatic-tnbc-and-delivers-q4-business-update-with-breakthroughs-across-breast-cancer-immuno-oncology-and-gbm-regulatory-strategy-302618635.html">added</a>. Kazia now plans to conduct a follow-up scan to confirm the initial scan.</p><h2 class="st-heading-2">Executive Commentary</h2><p>"Observing an initial complete response in a patient with metastatic triple-negative breast cancer is an extremely encouraging clinical finding," said CEO John Friend.</p><p>Paxalisib was licensed from Genentech in late 2016 and is being developed to treat multiple forms of cancer. The company now intends to request a meeting with the U.S. Food and Drug Administration to discuss the overall survival Paxalisib findings from its completed clinical studies and to discuss the elements needed for an application submission for Paxalisib in newly diagnosed glioblastoma.</p><h2 class="st-heading-2">Delisting Concerns</h2><p>Kazia on Tuesday also raised concerns about a potential suspension or delisting of its shares from Nasdaq, as it is not in compliance with certain listing rules. The company said it intends to request a hearing before a Nasdaq panel in a timely manner to stay any suspension or delisting action pending the outcome of the hearing.</p><p>The company is now also evaluating corporate and market-based options to regain compliance.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:585/56;" src="data:image/png;base64,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" width="585" height="56" alt="KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits"><figcaption>KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits</figcaption></figure><p>KZIA stock is down by 8% this year and by about 71% over the past 12 months.</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alkermes-to-acquire-avadel-for-up-to-2.37-billion-after-lundbeck-proposal/cLPoIyoREB2">Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Rising stock market chart on a trading board background.

KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination

Kazia now plans to conduct a follow-up scan to confirm the initial scan. 

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$5.72
Prev Close	$5.79
Open	$5.80
Dividend Yield	0.00%
50-Day Moving Average	$8.42
Beta	1.26
Avg. Volume	290,176.95
PE Ratio	-0.46

52-Week High	$17.40
52-Week Low	$2.86
Market Capitalization	$9.56M
EPS (Annual)	-$12.23
Price to Book	-1.70
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

KZIA
Kazia Therapeutics

Feed

News

Sentiment

Fundamentals

Info

Latest KZIA News

KZIAKazia Therapeutics